Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
The National Centre For Cell Science maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution activity is handled by 1 distinct examiner operating within 1 distinct art unit. The concentration of the portfolio in this specific technology area reflects the center's specialized research focus. This single pending office action represents the current state of the center's patent office interactions.
NOLAN, JASON MICHAEL is identified as the busiest examiner, with 1 pending office action under review. As there is only 1 pending office action for the entire portfolio, this examiner is responsible for all current interactions with the patent office. The 1 distinct examiner and 1 distinct art unit provide a very specific point of contact for the center's intellectual property matters.
The presence of 1 distinct art unit for the 1 pending office action suggests a consistent examination environment. Practitioners managing this portfolio deal with a single examiner and a single set of art unit standards. This centralized approach in the Biotechnology & Pharmaceuticals area allows for a focused prosecution strategy for the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOLAN, JASON MICHAEL | 1 | 66.6% | -27.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18696916 | NOVEL COMBINATION OF SEROTONIN RECEPTOR (5-HTR2B) ANTAGONIST AND AN IMMUNOMODULATOR AND CHEMOTHERAPEUTIC DRUGS FOR INHIBITION OF CANCER | NOLAN, JASON MICHAEL | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18696916 | NOVEL COMBINATION OF SEROTONIN RECEPTOR (5-HTR2B) ANTAGONIST AND AN IMMUNOMODULATOR AND CHEMOTHERAPEUTIC DRUGS FOR INHIBITION OF CANCER | NOLAN, JASON MICHAEL | 1623 | §103§112 | Non-Final OA | — | Pending | Mar 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNational Centre For Cell Science has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jason Michael Nolan has the most, with 1 of National Centre For Cell Science's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
